We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Ingestible Pill-Sized Device Safely Monitors Vital Signs from Within Patient’s GI Tract

By HospiMedica International staff writers
Posted on 22 Nov 2023

In recent years, scientists have made significant strides in developing a range of ingestible devices. More...

These devices, unlike implantable ones such as pacemakers, offer ease of use without the need for surgical procedures. An example of this technology in action is the use of pill-sized cameras for non-invasive colonoscopies. Building upon this concept, scientists have now introduced an innovative ingestible device designed to monitor vital signs like heart rate and breathing from within the body. This device shows potential for offering convenient care for individuals at risk of opioid overdose.

Created by Celero Systems (Lincoln, MA, USA), the vitals-monitoring pill (VM Pill) functions by detecting the subtle vibrations produced by heartbeat and respiratory movements. It is especially useful in identifying breathing cessation, a critical condition often associated with opioid overdoses, from within the digestive tract. To validate the effectiveness of the VM Pill, it was tested in anesthetized pigs. The pigs received a dose of fentanyl to simulate the conditions of an overdose, causing them to stop breathing. Remarkably, the pill successfully monitored the pigs' breathing rates in real-time, allowing researchers to intervene and reverse the overdose effects.

The VM Pill was also trialed in humans for the first time with individuals undergoing sleep apnea evaluations. It effectively detected pauses in breathing and tracked respiration rates with a 92.7% accuracy rate. When compared to external monitoring devices, this pill showed at least 96% accuracy in heart rate monitoring. The trials confirmed the pill's safety, with participants naturally excreting the device within a few days post-experiment. Currently, the VM Pill is designed to pass through the body in about a day, but future enhancements aim to extend its duration in the body for more prolonged monitoring. Additionally, there are plans to upgrade the pill to automatically administer medication in response to detected conditions like opioid overdose.

“The idea of using an ingestible device is that a physician can prescribe these capsules, and all the patient needs to do is to swallow it,” said Benjamin Pless, the founder of Celero Systems. “People are accustomed to taking pills, and costs of using ingestible devices are much more affordable than performing traditional medical procedures.”

Related Links:
Celero Systems


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.